Terms: = Leukemia AND MALT1, ENSG00000172175, 10892 AND Treatment
9 results:
1. Profiling the activity of the para-caspase malt1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application.
Safa FM; Rasmussen T; Fontan L; Xia M; Melnick A; Wiestner A; Lobelle-Rich P; Burger JA; Mouawad Y; Safah H; Flemington EK; Saba NS
Haematologica; 2024 May; 109(5):1348-1358. PubMed ID: 37767562
[TBL] [Abstract] [Full Text] [Related]
2. Dimethyl Fumarate Suppresses the Proliferation of HTLV-1-infected T Cells by Inhibiting CBM Complex-triggered NF-B Signaling.
Sato T; Maeta T; Ito S
Anticancer Res; 2023 May; 43(5):1901-1908. PubMed ID: 37097671
[TBL] [Abstract] [Full Text] [Related]
3. Cotargeting of BTK and malt1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.
Jiang VC; Liu Y; Lian J; Huang S; Jordan A; Cai Q; Lin R; Yan F; McIntosh J; Li Y; Che Y; Chen Z; Vargas J; Badillo M; Bigcal JN; Lee HH; Wang W; Yao Y; Nie L; Flowers CR; Wang M
J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36719376
[TBL] [Abstract] [Full Text] [Related]
4. Blood malt1 deficiency is common and relates to unfavorable induction therapy response and survival profile in acute myeloid leukemia patients.
Geng H; Wang Y; Wang S
Hematology; 2022 Dec; 27(1):1176-1183. PubMed ID: 36314929
[TBL] [Abstract] [Full Text] [Related]
5. Anticancer Activity of Lesbicoumestan in Jurkat Cells via Inhibition of Oxidative Stress-Mediated Apoptosis and malt1 Protease.
Lee JE; Bo F; Thuy NTT; Hong J; Lee JS; Cho N; Yoo HM
Molecules; 2021 Jan; 26(1):. PubMed ID: 33401649
[TBL] [Abstract] [Full Text] [Related]
6. [Diagnostic and therapeutic values of interphase fluorescence in situ hybridization in B-cell lymphomas: a clinicopathologic analysis of 604 cases].
Chen M; Yang JL; Zhao S; Liu WP; Li GD; Ye YX; Yan JQ; Zhang WY
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):920-925. PubMed ID: 30522172
[No Abstract] [Full Text] [Related]
7. malt1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic leukemia.
Saba NS; Wong DH; Tanios G; Iyer JR; Lobelle-Rich P; Dadashian EL; Liu D; Fontan L; Flemington EK; Nichols CM; Underbayev C; Safah H; Melnick A; Wiestner A; Herman SEM
Cancer Res; 2017 Dec; 77(24):7038-7048. PubMed ID: 28993409
[TBL] [Abstract] [Full Text] [Related]
8. TNFAIP3 promotes survival of CD4 T cells by restricting MTOR and promoting autophagy.
Matsuzawa Y; Oshima S; Takahara M; Maeyashiki C; Nemoto Y; Kobayashi M; Nibe Y; Nozaki K; Nagaishi T; Okamoto R; Tsuchiya K; Nakamura T; Ma A; Watanabe M
Autophagy; 2015; 11(7):1052-62. PubMed ID: 26043155
[TBL] [Abstract] [Full Text] [Related]
9. Cellular proteolytic modification of tumor-suppressor CYLD is critical for the initiation of human T-cell acute lymphoblastic leukemia.
Arora M; Kaul D; Varma N; Marwaha RK
Blood Cells Mol Dis; 2015 Jan; 54(1):132-8. PubMed ID: 25130432
[TBL] [Abstract] [Full Text] [Related]
